About Ark Biotech
Ark Biotech is a Consumer company based in Boston (United States) founded in 2021 by Yossi Quint. Bioreactors and systems for cultivated meat production are developed. It operates in the Consumer and Healthcare sectors. Ark Biotech has raised $10.68 million across 2 funding rounds from investors including Primary. Its chief executive, as recorded, is Yossi Quint. Ark Biotech offers products and services including Simulation Software and Bioreactor Model. Its focus areas include Food and Agriculture Tech, Food Tech, Novel Foods and Food Products. Its competitors include PBS Biotech, Hyalose and Distek; 1 of its 3 listed competitors has raised funding.
Company details
Ark Biotech was founded in 2021 and is based in Boston, United States. Operations focus on the biotechnology sector, where bioreactors and associated operating systems are manufactured for the industrial-scale production of cultivated meat. Development efforts target scalable solutions to support this emerging protein technology, with activities centered on hardware and software integration for efficient cultivation processes.
- Headquarters Boston, United States
- Founders Yossi Quint
- SectorsConsumerHealthcare
- Email••••••••
- Website ark-biotech.com
- Social LinkedIn
- Total Equity Funding$10.68M (USD)
in 2 rounds
- Latest Funding Round$8.18M (USD), Series A
May 2024
- Investors
Products & Services of Ark Biotech
Ark Biotech offers a comprehensive portfolio of products and services, including Simulation Software and Bioreactor Model.
Software for virtual bioreactor simulations to optimize bioprocess parameters.
Tool for predicting cell culture trends and scaling processes efficiently.
Funding Insights of Ark Biotech
Ark Biotech has successfully raised a total of $10.68M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $8.18 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10.68M
- Total Rounds 2
- Last Round Series A — $8.18M
- First Round $2.5M
(Dec 2021)
- Investors Count 1
All 2 funding rounds of Ark Biotech with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2024 | $8.18M | Series A | – | – | – |
| Dec 2021 | $2.5M | Seed | – | – |
1 investors in total: 1 institutional.
Investors in Ark Biotech
Ark Biotech has secured backing from 1 investor, including venture fund investors. Prominent investors backing the company include Primary.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments in seed-stage companies are managed by Primary Venture Partner. | primary.vc | New York, United States |
Investor details for Ark Biotech
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Ark Biotech
4 people are tracked at Ark Biotech (2 in leadership, 2 in team).
| Name | Role | Group |
|---|---|---|
Yossi Quint | Founder & CEO | Leadership |
Zheng Huang | Chief Technology Officer | Leadership |
Sean Kim | Senior Bioprocess Engineer | Team |
Elizabeth Ter Sahakyan | Senior Product Manager | Team |
Complete people profiles for Ark Biotech
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Ark Biotech
3 dated milestones of Ark Biotech across 3 years, from founding to its latest funding, stage changes and deals.
- Founded Ark Biotech is founded.
- Funding First funding round of $2.5M.
- Funding Latest funding round, Series A, of $8.2M.
Competitors of Ark Biotech
Ark Biotech has 3 listed competitors in our database, 1 of them funded. They include PBS Biotech, Hyalose and Distek.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| pbsbiotech.com | 2006 | Camarillo, United States | $70.21M | Developer of single-use bioreactors for the production of vaccines, therapeutic proteins, and cell therapies | ||
| hyalose.com | 2000 | Oklahoma, United States | Recombinant hyaluronic acid is manufactured in varying molecular sizes. | |||
| distekinc.com | 1976 | North Brunswick, United States | 58 | Produces dissolution apparatus and bioprocessing equipment for pharmaceutical testing. |
Detailed competitors of Ark Biotech
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Ark Biotech
The website of Ark Biotech (ark-biotech.com) receives about 2.9K visits a month.
- Monthly visits2.9K
▼ 20.5% vs previous month
Top companies in Food & Beverage Platforms
3 companies that operate in the same segment as Ark Biotech (Food & Beverage Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Food and grocery deliveries are facilitated through an app-based platform. | 2013 | San Francisco, California, United States | USD 2.5 B | USD 10.72 B | 80,579 | |
Platform for discovering and sharing local businesses | 2004 | San Francisco, California, United States | USD 56 M | USD 1.46 B | 5,120 | |
Restaurant operations are managed via a cloud-based platform. | 2011 | Boston, Massachusetts, United States | USD 900 M | USD 6.15 B | 8,021 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Ark Biotech
Complete news archive for Ark Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Ark Biotech
Ark Biotech was founded in 2021.
Ark Biotech is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
Yossi Quint is the CEO of Ark Biotech, as recorded in our data. They have also founded this company.
Ark Biotech is a funded company, having raised a total of $10.68M across 2 funding rounds to date. The company's 1st funding round was a Seed of $2.5M, raised on Dec 2021.
Ark Biotech was founded in 2021 and is based in Boston, United States. Operations focus on the biotechnology sector, where bioreactors and associated operating systems are manufactured for the industrial-scale production of cultivated meat. Development efforts target scalable solutions to support this emerging protein technology, with activities centered on hardware and software integration for efficient cultivation processes.
Ark Biotech's top competitors include PBS Biotech, Hyalose and Distek.
Ark Biotech offers Simulation Software and Bioreactor Model.
Ark Biotech has 1 investor. Key investors include Primary.